Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Quizartinib Dihydrochloride

FDA-approved product (tablet, oral), marketed as Vanflyta.

Registered studies
4
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Quizartinib Dihydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute myeloid leukemia
  • Myeloid leukemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA70.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli51.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

4registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Quizartinib Dihydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-3.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Quizartinib Dihydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of SA+X in the Treatment of Newly Diagnosed AML

    NCT07548710 · start 2026-05-01

    Registered record
    Registry ID
    NCT07548710
    Conditions
    Acute Myeloid Leukemia
    Interventions
    Anthracycline; Ivosidenib; Gilteritinib; Sonrotoclax; Azacitidine (AZA); Quizartinib Dihydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-05-01
    Completion
    2028-12-21
    Enrolment
    205

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionAnthracycline; Ivosidenib; Gilteritinib; Sonrotoclax +2 more
    PhasePhase 2
    Registry statusRecruiting

  • A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy Subjects

    NCT04796831 · start 2021-04-26

    Registered record
    Registry ID
    NCT04796831
    Conditions
    Healthy Subjects
    Interventions
    Quizartinib dihydrochloride; 14C-Quizartinib solution for infusion
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-04-26
    Completion
    2021-06-11
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionQuizartinib dihydrochloride; 14C-Quizartinib solution for infusion
    PhasePhase 1
    Registry statusCompleted

  • Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

    NCT03793478 · start 2018-08-15

    Registered record
    Registry ID
    NCT03793478
    Conditions
    Acute Myeloid Leukemia
    Interventions
    Quizartinib; Fludarabine; Cytarabine; Intrathecal (IT) triple chemotherapy prophylaxis; Etoposide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2018-08-15
    Completion
    2027-05-01
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionQuizartinib; Fludarabine; Cytarabine; Intrathecal (IT) triple chemotherapy prophylaxis +1 more
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib

    NCT03746912

    Registered record
    Registry ID
    NCT03746912
    Conditions
    Acute Myeloid Leukemia With Gene Mutations
    Interventions
    Quizartinib Dihydrochloride
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia With Gene Mutations
    InterventionQuizartinib Dihydrochloride
    PhaseNot recorded
    Registry statusNo longer available